MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Predictive Oncology Operating Income 2011-2026 | POAI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -181 M | -10.3 M | -12.1 M | -26 M | -20.4 M | -25.4 M | -22.6 M | -7.86 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.86 M | -181 M | -38.2 M |
Quarterly Operating Income Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.28 M | -2.66 M | -2.29 M | - | -2.16 M | -2.46 M | -3.58 M | - | -2.74 M | -3.96 M | -3.46 M | - | -4.13 M | -10.5 M | -3.41 M | - | -5.49 M | -2.6 M | -3.78 M | - | -5.61 M | -3.77 M | -3.44 M | - | -3.44 M | -5.1 M | -2.34 M | - | -1.86 M | -1.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.41 M | -10.5 M | -3.63 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
683 M | $ 60.58 | 0.33 % | $ 12.1 B |  USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 115.46 | 1.14 % | $ 3.7 B | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 120.37 | -2.13 % | $ 2.97 B | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 3.87 | -2.76 % | $ 179 M | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 421.73 | -1.48 % | $ 151 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 97.52 | -1.99 % | $ 2.21 B | USA |
 |
Alcon
ALC
|
580 M | $ 63.93 | -0.14 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
-267 M | $ 178.4 | 0.03 % | $ 9.51 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 23.69 | -0.67 % | $ 3.98 B | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 6.29 | -2.18 % | $ 53.4 K | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 56.6 | -0.86 % | $ 2.85 B | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 32.27 | 0.81 % | $ 1.6 B | USA |
 |
STERIS plc
STE
|
867 M | $ 214.08 | -0.88 % | $ 21.1 B | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 128.92 | -1.04 % | $ 5.75 B | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 141.43 | -0.52 % | $ 6.85 B | USA |
 |
InfuSystem Holdings
INFU
|
11.9 M | $ 8.57 | -0.46 % | $ 177 M | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 1.93 | 4.32 % | $ 88.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.33 | -1.64 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 62.4 | -0.26 % | $ 3.69 B | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 63.24 | -0.72 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 301.39 | 0.4 % | $ 21.8 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 24.12 | -11.01 % | $ 1.63 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 10.04 | -3.6 % | $ 2 B | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.69 | - | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 59.95 | 2.22 % | $ 197 M | USA |
 |
BioLife Solutions
BLFS
|
-16.6 M | $ 20.55 | -2.42 % | $ 981 M | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.87 | -3.86 % | $ 170 M | USA |
 |
Baxter International
BAX
|
-308 M | $ 17.32 | -2.64 % | $ 8.89 B | USA |
 |
ResMed
RMD
|
1 B | $ 202.53 | -0.01 % | $ 29.6 B | USA |
 |
AtriCure
ATRC
|
-9.45 M | $ 28.37 | 0.79 % | $ 1.35 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 5.36 | -2.9 % | $ 238 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.88 | -1.36 % | $ 444 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 142.79 | -1.2 % | $ 41.1 B | USA |
 |
Nephros
NEPH
|
1.15 M | $ 3.16 | -5.39 % | $ 33.5 M | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.08 | 4.24 % | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
55.2 M | $ 105.36 | 1.91 % | $ 5.92 M | USA |